Hepatitis C

"Hepatitis C" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Descriptor ID	D006526
MeSH Number(s)	C02.440.440 C02.782.350.350 C06.552.380.705.440
Concept/Terms	Hepatitis C Hepatitis C Parenterally-Transmitted Non-A, Non-B Hepatitis Parenterally Transmitted Non A, Non B Hepatitis PT-NANBH Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

Below are MeSH descriptors whose meaning is more general than "Hepatitis C".

Diseases [C]
Virus Diseases [C02]
Hepatitis, Viral, Human [C02.440]
Hepatitis C [C02.440.440]
RNA Virus Infections [C02.782]
Flaviviridae Infections [C02.782.350]
Hepatitis C [C02.782.350.350]
Digestive System Diseases [C06]
Liver Diseases [C06.552]
Hepatitis [C06.552.380]
Hepatitis, Viral, Human [C06.552.380.705]
Hepatitis C [C06.552.380.705.440]

Below are MeSH descriptors whose meaning is related to "Hepatitis C".

Below are MeSH descriptors whose meaning is more specific than "Hepatitis C".

Hepatitis C
Hepatitis C, Chronic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hepatitis C" by people in this website by year, and whether "Hepatitis C" was a major or minor topic of these publications.

Bar chart showing 82 publications over 27 distinct years, with a maximum of 7 publications in 2006

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	0	1	1
1999	1	0	1
2001	1	0	1
2002	2	0	2
2003	5	1	6
2004	5	0	5
2005	5	1	6
2006	4	3	7
2007	3	0	3
2008	1	2	3
2009	1	3	4
2010	3	0	3
2011	1	1	2
2012	2	0	2
2013	4	0	4
2014	1	1	2
2015	5	0	5
2016	3	2	5
2017	2	0	2
2018	2	0	2
2019	1	1	2
2020	3	1	4
2021	1	0	1
2022	4	0	4
2023	3	0	3
2024	1	0	1

Below are the most recent publications written about "Hepatitis C" by people in Profiles.

Hage K, Boyd A, Op de Coul ELM, Sarink D, Hoornenborg E, Prins M. Hepatitis C virus infection is uncommon at baseline and during follow-up among individuals using PrEP in the Dutch national PrEP programme between 2019 and 2022. Sex Transm Infect. 2024 Jul 26; 100(5):288-294.

View in: PubMed
Gandhi MM, Nguyen KL, Lake JE, Liao D, Khodabakhshian A, Guerrero M, Shufelt CL, Bairey Merz CN, Jordan WC, Daar ES, Bhattacharya D, Chew KW. Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation. AIDS. 2024 03 01; 38(3):317-327.

View in: PubMed
Col?n-L?pez V, Alvelo-Fern?ndez PM, Centeno-Alvarado N, Agudelo Salas IY, Rol?n Col?n Y, Pab?n Mart?nez M, Rodr?guez-Lebr?n JL, Reyes-Pulliza JC. Seroprevalence and risk factors associated with hepatitis C: a cross-sectional study of persons who inject drugs in Puerto Rico, 2018. BMC Public Health. 2023 04 18; 23(1):704.

View in: PubMed
Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prev Res (Phila). 2023 03 01; 16(3):163-173.

View in: PubMed
Anastario M, Firemoon P, Rodriguez AM, Wade C, Prokosch C, Rink E, Wagner E. A Pilot Study of Polysubstance Use Sequences across the Lifespan among Assiniboine and Sioux People Who Use Injection Drugs. Int J Environ Res Public Health. 2022 12 29; 20(1).

View in: PubMed
Jiang X, Diaby V, Vouri SM, Lo-Ciganic W, Parker RL, Wang W, Chang SH, Wilson DL, Henry L, Park H. Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. Am J Prev Med. 2023 01; 64(1):96-104.

View in: PubMed
Ozga JE, Syvertsen JL, Pollini RA. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California. J Viral Hepat. 2022 07; 29(7):518-528.

View in: PubMed
Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, Siriwardhana C, Chow D, Ghukasyan H, Limpruttidham N, Premeaux T, Gangcuangco LM, Paul R, Ndhlovu LC. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS Res Hum Retroviruses. 2022 06; 38(6):441-450.

View in: PubMed
Islam JY, Spees L, Camacho-Rivera M, Vidot DC, Yarosh R, Wheldon CW. Disparities in Awareness of Hepatitis C Virus Among US Adults: An Analysis of the 2019 Health Information National Trends Survey. Sex Transm Dis. 2021 12 01; 48(12):981-985.

View in: PubMed
Sims OT, Wang K, Chandler R, Melton PA, Truong DN. A descriptive analysis of concurrent alcohol and substance use among patients living with HIV/HCV co-infection. Soc Work Health Care. 2020 08; 59(7):525-541.

View in: PubMed

People

Explore

Similar Concepts

Top Journals